IBDEI0EN ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6298,2)
 ;;=^5054344
 ;;^UTILITY(U,$J,358.3,6299,0)
 ;;=T81.718A^^53^406^21
 ;;^UTILITY(U,$J,358.3,6299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6299,1,3,0)
 ;;=3^Complication of Artery Following Procedure NEC,Init Encntr
 ;;^UTILITY(U,$J,358.3,6299,1,4,0)
 ;;=4^T81.718A
 ;;^UTILITY(U,$J,358.3,6299,2)
 ;;=^5054644
 ;;^UTILITY(U,$J,358.3,6300,0)
 ;;=T81.72XA^^53^406^26
 ;;^UTILITY(U,$J,358.3,6300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6300,1,3,0)
 ;;=3^Complication of Vein Following Procedure NEC,Init Encntr
 ;;^UTILITY(U,$J,358.3,6300,1,4,0)
 ;;=4^T81.72XA
 ;;^UTILITY(U,$J,358.3,6300,2)
 ;;=^5054650
 ;;^UTILITY(U,$J,358.3,6301,0)
 ;;=T82.817A^^53^406^30
 ;;^UTILITY(U,$J,358.3,6301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6301,1,3,0)
 ;;=3^Embolism of Cardiac Prosthetic Device/Implant/Graft,Init Encntr
 ;;^UTILITY(U,$J,358.3,6301,1,4,0)
 ;;=4^T82.817A
 ;;^UTILITY(U,$J,358.3,6301,2)
 ;;=^5054914
 ;;^UTILITY(U,$J,358.3,6302,0)
 ;;=T82.818A^^53^406^31
 ;;^UTILITY(U,$J,358.3,6302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6302,1,3,0)
 ;;=3^Embolism of Vascular Prosthetic Device/Implant/Graft,Init Encntr
 ;;^UTILITY(U,$J,358.3,6302,1,4,0)
 ;;=4^T82.818A
 ;;^UTILITY(U,$J,358.3,6302,2)
 ;;=^5054917
 ;;^UTILITY(U,$J,358.3,6303,0)
 ;;=I27.0^^53^406^61
 ;;^UTILITY(U,$J,358.3,6303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6303,1,3,0)
 ;;=3^Primary Pulmonary Hypertension
 ;;^UTILITY(U,$J,358.3,6303,1,4,0)
 ;;=4^I27.0
 ;;^UTILITY(U,$J,358.3,6303,2)
 ;;=^265310
 ;;^UTILITY(U,$J,358.3,6304,0)
 ;;=I27.1^^53^406^47
 ;;^UTILITY(U,$J,358.3,6304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6304,1,3,0)
 ;;=3^Kyphoscoliotic Hrt Disease
 ;;^UTILITY(U,$J,358.3,6304,1,4,0)
 ;;=4^I27.1
 ;;^UTILITY(U,$J,358.3,6304,2)
 ;;=^265120
 ;;^UTILITY(U,$J,358.3,6305,0)
 ;;=I27.89^^53^406^66
 ;;^UTILITY(U,$J,358.3,6305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6305,1,3,0)
 ;;=3^Pulmonary Hrt Diseases NEC
 ;;^UTILITY(U,$J,358.3,6305,1,4,0)
 ;;=4^I27.89
 ;;^UTILITY(U,$J,358.3,6305,2)
 ;;=^5007153
 ;;^UTILITY(U,$J,358.3,6306,0)
 ;;=I27.81^^53^406^29
 ;;^UTILITY(U,$J,358.3,6306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6306,1,3,0)
 ;;=3^Cor Pulmonale,Chronic
 ;;^UTILITY(U,$J,358.3,6306,1,4,0)
 ;;=4^I27.81
 ;;^UTILITY(U,$J,358.3,6306,2)
 ;;=^5007152
 ;;^UTILITY(U,$J,358.3,6307,0)
 ;;=I42.1^^53^406^51
 ;;^UTILITY(U,$J,358.3,6307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6307,1,3,0)
 ;;=3^Obstructive Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,6307,1,4,0)
 ;;=4^I42.1
 ;;^UTILITY(U,$J,358.3,6307,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,6308,0)
 ;;=I42.2^^53^406^46
 ;;^UTILITY(U,$J,358.3,6308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6308,1,3,0)
 ;;=3^Hypertrophic Cardiomyopathy NEC
 ;;^UTILITY(U,$J,358.3,6308,1,4,0)
 ;;=4^I42.2
 ;;^UTILITY(U,$J,358.3,6308,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,6309,0)
 ;;=I42.5^^53^406^67
 ;;^UTILITY(U,$J,358.3,6309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6309,1,3,0)
 ;;=3^Restrictive Cardiomyopathy NEC
 ;;^UTILITY(U,$J,358.3,6309,1,4,0)
 ;;=4^I42.5
 ;;^UTILITY(U,$J,358.3,6309,2)
 ;;=^5007196
 ;;^UTILITY(U,$J,358.3,6310,0)
 ;;=I42.6^^53^406^11
 ;;^UTILITY(U,$J,358.3,6310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6310,1,3,0)
 ;;=3^Alcoholic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,6310,1,4,0)
 ;;=4^I42.6
 ;;^UTILITY(U,$J,358.3,6310,2)
 ;;=^5007197
